65,437 trials
Seasonal Allergic Rhinitis
Primary: Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline — 4.28; 4.15 Units on a scale
Hyponatremia
Primary: Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. — 126.03; 126.39; 125.55; 130.4 mEq/L — p=0.028
Parkinson Disease
Primary: Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population) — 9.4; 8.9; 8.2; 8.1 points on a scale
Attention Deficit/ Hyperactivity Disorder
Primary: Attention Deficit/Hyperactivity Disorder (ADHD) Symptoms Total Score of the Conners Adult ADHD Rating Scale (CAARS) — 36.5; 35.6; 37.3; 26.1 units on a scale — p=0.136
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain — 28.0; 28.3; 8.4…
Non-Small Cell Lung Cancer · Carcinoma
Primary: High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Flexible Bronchoscopy
Primary: The Number of Participants With Any Hypoxemia Event During Flexible Bronchoscopy — 97; 88 participants — p=0.05
Migraine Disorders
Primary: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose — 10; 41 Participants — p=<0.001
Healthy
Primary: Maximum Concentration (Cmax) of Venlafaxine After Single Dose of Venlafaxine Extended-release (VEN ER) by Metabolizer Status — 26.16; 77.46 ng/mL (90% CI) — p=<0.001
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -0.85; -0.15 Percent — p=<0.001
Bipolar Disorder
Primary: Number of Participants Who Experienced an Adverse Event — 32; 25 Participants
Cataract
Primary: Visual Acuity — 0.07; 0.07; 0.02; 0.06 logMAR
Early Parkinson Disease (Early PD)
Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score — -8.6; -8.8; -3.8 units on a scale
Melanoma · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01
Insulin-Like Growth Factor-1 Deficiency · Growth Disorders
Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)